Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Karuna Therapeutics Inc (KRTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Karuna Therapeutics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Karuna Therapeutics historical data, for real-time data please try another search
329.83 +0.00    +0.00%
15/03 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 329.83 / 329.94
  • Day's Range: 329.75 - 329.97
Karuna Therapeutics 329.83 +0.00 +0.00%

Karuna Therapeutics Inc Company Profile

 
Get an in-depth profile of Karuna Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

339

Equity Type

ORD

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. As of March 18, 2024, Karuna Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

Contact Information

Address 99 High Street 26th Floor
Boston, 02110
United States
Phone 857 449 2244
Fax -
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

KRTX Comments

Write your thoughts about Karuna Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
jonathan ehlebracht
jonathan ehlebracht Apr 01, 2020 12:16PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
LOL. Hurry sell everything based on nothing.....
jonathan ehlebracht
jonathan ehlebracht Feb 27, 2020 1:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Huge potential for this year and next!
Episcopolian OptionTrader
Episcopolian1 Dec 27, 2019 3:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Lock-up expires TODAY. Insiders will start selling next week. Be aware!. $KRTX
Nj Paust
Nj Paust Nov 21, 2019 11:00PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Days range is 77.50 to 102. Be careful out there!
Dan Benzo
Dan Benzo Nov 20, 2019 12:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I missed this one! Argh
Logan VanGorder
Logan VanGorder Nov 19, 2019 4:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I just shorted the stock and lost my house
Vik Shah
Vik Shah Nov 19, 2019 10:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
day traders heaven..seems like..be careful..lol
blue sky
blue_sky Nov 19, 2019 12:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nobody going to say anything?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email